The breakpoints used to interpret antimicrobial susceptibility tests should be carefully determined initially, using microbiological, pharmacokinetic, pharmacodynamic, and clinical data, and then reevaluated periodically as changes in bacterial resistance, susceptibility test methods, or antibiotic formulations occur. Throughout the world, different governmental agencies and professional organizations have responsibility for the initial establishment of antibiotic susceptibility breakpoints. In the United States, the National Committee for Clinical Laboratory Standards has a mechanism in place to establish breakpoints initially and to review and publish updates on an annual basis. There should be a continued effort to coordinate both susceptibility testing methods and breakpoint determinations in various parts of the world.
It is easy to affirm that antibiotic breakpoints used in the interpretation of susceptibility tests should sometimes be reevaluated; all guidelines could benefit from periodic reevaluation. However, the immediacy of the need to change these breakpoints is unclear. Moreover, because there are many regulatory agencies and professional organizations around the world that are responsible for establishing breakpoints, whether a single set of breakpoints for interpreting antimicrobial susceptibility tests can emerge is also unclear. This paper reviews several issues associated with the establishment of antibiotic susceptibility breakpoints and outlines the consensus process used by the National Committee for Clinical Laboratory Standards (NCCLS) in establishing breakpoints, including correlation of microbiological with pharmacokinetic and pharmacodynamic data and, where possible, with data from clinical studies.
MULTIPLE RESPONSIBLE AGENCIES
Around the world, several governmental agencies and other professional organizations are responsible for the initial establishment of antibiotic susceptibility break-points for their countries or regions. In the United States, the Food and Drug Administration (FDA) has governmental oversight in this area and includes breakpoints in the labeling of newly approved antimicrobial agents. In Europe, the recently formed Committee for Proprietary Medicinal Products has assumed some responsibility, as have other, more traditional governmental agencies in individual countries. In addition, nongovernmental consensus organizations or professional societies have some responsibility for these recommendations. For example, in the United States, the NCCLS meets regularly to review and approve antibiotic breakpoints and to issue annual guidelines and consensus documents [1, 2] . In Europe, a recently organized subcommittee of the European Society of Clinical Microbiology and Infectious Diseases, the European Committee on Antibiotic Susceptibility Testing, may publish European guidelines in the future. Currently, a few countries have professional groups (e.g., the British Society for Antimicrobial Chemotherapy, in the United Kingdom; the Society Française Medicale, in France; the Deutsches Institut für Normung, in Germany; Mensura, in Spain; and additional groups in Scandinavia) that issue recommendations or speak on these issues.
The FDA does not have a formal process for changing breakpoints. Once initial breakpoints are established for product labeling for a new drug, they are not reviewed or changed at a later time. This can result in the use of inappropriate breakpoints for organisms that may show decreased susceptibility with the passage of time. On the other hand, the NCCLS establishes initial breakpoints and then reviews them periodically and can publish changed or updated breakpoints on an annual basis [3] .
In addition, selected breakpoints for a given drug against a given organism may differ among many countries. For example, as seen in table 1, among the United States and 5 European countries the susceptibility breakpoints for cefotaxime and ceftazidime range from р1 to р8 mg/mL. These differences may result from different dosing of drugs in various countries or from use of different laboratory methods to determine antibiotic susceptibility. In addition, some philosophical differences may exist among the various organizations and societies responsible for issuing these breakpoints.
The Subcommittee on Antimicrobial Susceptibility Testing of the NCCLS uses a combination of microbiological, pharmacokinetic, pharmacodynamic, and clinical data to establish breakpoints [4] . Microbiological considerations require that population distributions of relevant clinical isolates be used, as well as bacterial strains that demonstrate important resistance characteristics, some of which may have been identified with molecular methods. The relevant pharmacokinetic and pharmacodynamic considerations include the peak serum or CSF levels, area under the serum concentration time curve (AUC), time above the MIC, and other considerations. In addition, different dosing regimens suggested for different types of infection are also considered. Bacteriologic eradication and clinical responses for organisms with varying MICs and zone diameters are studied. In certain cases for which there is a need to establish breakpoints for older antibiotics and new clinical data are not available (e.g., for viridans group streptococci), clinical correlations are based on data in the literature. The details of this process are found in the NCCLS guideline Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters [4] .
PROBLEMS WITH CURRENT BREAKPOINT DATA
The establishment of breakpoints is generally easy when the population of bacteria studied can be separated into clear-cut groups. Bimodal curves are obviously easy to correlate with susceptibility and resistance. However, when the distributions of MICs or zone diameters are unimodal or trimodal, it may be very difficult to make appropriate breakpoint determinations. In addition, when molecular aspects of resistance are considered, some genotypic resistance may not be expressed phenotypically, as with the normal, chromosomal ampC gene in Escherichia coli, for example. Small shifts upward in MICs may not manifest clinically, and 11 mutation may be required before resistance is expressed either clinically or in the laboratory. Moreover, not all the molecular mechanisms responsible for antibiotic resistance are known, and, if they were, it is not clear that all mutations would be relevant to the calculation of breakpoint data.
Pharmacokinetic and pharmacodynamic considerations are also problematic. The serum levels chosen might not be relevant to all infection sites. In addition, the pharmacokinetics of any given drug may be relatively consistent from patient to patient, but there may be a wide range in the MICs of some infecting organisms. Pharmacodynamic parameters used to predict outcome, such as the ratio of peak serum concentration to MIC and the AUC:MIC ratio, will vary considerably if the MIC at the breakpoint is used instead of the MIC 50 or MIC 90 , for example. This is illustrated in table 2 for the activity of a particular fluoroquinolone against Streptococcus pneumoniae at a single daily oral dose. The peak:MIC ratio varies 35-fold, depending on which MIC determination is used. A similarly wide range in the AUC:MIC ratio can be seen in the same hypothetical example (table 2) .
The use of clinical data to establish breakpoints can be useful and confirmatory when the relationship between the data and the breakpoints is clear-cut. However, clinical correlations may be problematic, because most studies do not include enough patients who are infected with highly resistant organisms. This, as well as inadequate study design, may result in excessive type 2 or beta errors in the interpretation of these data. Some infections may be cured spontaneously, and this may complicate interpretation of clinical correlative data even further. The NCCLS generally uses the microbiological eradication data rather than clinical outcome (e.g., patient was cured or patient improved) data to set their breakpoint recommendations.
WHEN SHOULD BREAKPOINTS BE REASSESSED?
Existing breakpoint determinations also may be problematic if they were established when a particular species was susceptible to a given antibiotic. These breakpoints may not be applicable when bacterial strains begin to develop resistance to that antibiotic. For example, the disk diffusion test zone size that was originally used to establish susceptibility of vancomycin against enterococci did not apply to vancomycin-resistant enterococci and was changed when the existence of such microorganisms was recognized. Obviously, determinations of "susceptible" or "resistant" by MIC methods were still appropriate. One solution to this problem is to attempt to establish a conservative breakpoint close to that of the unimodal, susceptible population, so that shifts in susceptibility may be detected more readily.
Breakpoints might be appropriately reassessed when infections caused by organisms with new mechanisms of resistance increase in frequency and when these bacterial strains are not reliably detected by use of the available breakpoints. Examples of this problem include mecA-containing coagulase-negative staphylococci, which might not be appropriately detected by the former oxacillin zone diameter breakpoint used in disk diffusion testing. This has now been corrected. Another example is the detection of organisms that contain extended-spectrum b-lactamases (ESBLs), which might be resistant to extended-spectrum cephalosporins. In this case, the NCCLS developed screening and phenotypic confirmation methods for Klebsiella and E. coli containing ESBLs only after an assessment of the clinical impact of this resistance. The traditional extended-spectrum cephalosporin breakpoints remain unchanged, to prevent the unnecessary or excessive use of carbapenems in all cases (e.g., for urinary tract infections) in which microorganisms containing ESBLs are reported.
Breakpoints also can be reassessed when new clinical situations suggest such a need. For example, in the treatment of pneumococcal meningitis caused by penicillin-and cephalosporinresistant strains, the establishment of new breakpoints for cefotaxime and ceftriaxone was appropriate. Different breakpoints for susceptibility are useful in the treatment of pneumococcal pneumonia with oral and with parenteral b-lactam drugs, allowing treatment with these agents to circumvent strains with increasing penicillin MICs. Similarly, if new dosages or formulations of older antibiotics become available or if there are changes in clinical usage, a reconsideration of breakpoints may be necessary. For example, should breakpoints differ for a new iv preparation of an older oral antibiotic or when new formulations or higher doses of oral agents are approved?
It also should be remembered that the establishment of breakpoints is clearly linked to the method used to determine these data, and new media or new methods, such as the Etest (AB Biodisk), the use of CO 2 incubation, and others, may in fact have an impact on the MIC breakpoint values.
SUMMARY
Whenever new antibiotics are introduced or when breakpoints are first established, it is critically important that the determination be made correctly the first time. Whenever the need arises to reassess established breakpoints, it is important that this be evaluated in a fair and open process, using appropriate and adequately collected microbiological, pharmacokinetic, and, if possible, clinical data, to ensure the greatest usefulness of the information obtained. A continued effort should be made to coordinate susceptibility testing methods and breakpoint determinations in various parts of the world.
